US Army Ph II trials of Neuren's Glypromate

Australia's Neuren Pharmaceuticals says that physicians from Madigan Army Medical Center in Tacoma, Washington, USA, will conduct an investigator- initiated Phase II trial to determine the safety and efficacy of Glypromate (glycine-proline-glutamate) in reducing brain injury caused by out of hospital cardiac arrest. The trial will start in mid-2007 and will be managed by The Henry M Jackson Foundation for the Advancement of Military Medicine (Jackson Foundation) in consultation with the clinical investigators at Madigan.

The proposed study will be an investigator-initiated trial, which means that the Investigational New Drug application will be submitted to the Food and Drug Administration by the Army investigators rather than by Neuren. The company will provide the drug product as well as access to preclinical, clinical and regulatory documents related to Glypromate. The firm's only financial commitment will be compensation to the Jackson Foundation for administrative costs incurred in coordinating the study. Neuren will retain all commercial rights to Glypromate in these indications.